

Xue Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7834/publications.pdf>

Version: 2024-02-01

10
papers

2,082
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

4066
citing authors

#	ARTICLE	IF	CITATIONS
1	The CD8 ⁺ PIR ⁺ interaction maintains CD8 ⁺ T cell quiescence. <i>Science</i> , 2022, 376, 996-1001.	12.6	9
2	A Burned-Out CD8 ⁺ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1700-1715.	9.4	86
3	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1922-1935.	1.2	33
4	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. <i>Scientific Reports</i> , 2021, 11, 13482.	3.3	13
5	Structural insight into T cell coinhibition by PD-1H (VISTA). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1648-1657.	7.1	29
6	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 656-666.	30.7	461
7	PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	90
8	Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, 1-25.	3.2	22
9	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	8.2	1,112
10	Coinhibitory receptor PD-1H preferentially suppresses CD4 ⁺ T cell-mediated immunity. <i>Journal of Clinical Investigation</i> , 2014, 124, 1966-1975.	8.2	227